September 29, 2014 / 11:39 AM / 4 years ago

BUZZ-U.S. Stocks on the Move-DreamWorks, Athlon, Alimera, PSivida

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for more market insights, including options activity, ; for the Day Ahead newsletter,; for the Morning News Call newsletter,

U.S. stock index futures were lower on Monday, indicating Wall Street’s recent weakness would continue amid ongoing civil unrest in Hong Kong. Dow Jones industrial average futures were down 0.59 percent at 16,930, S&P 500 futures were down 0.63 percent at 1,963.5 and Nasdaq 100 futures were down 0.66 percent at 4,019.

** ATHLON ENERGY INC, Friday close $46.73, +24.46 pct premarket

** ENCANA CORP, Friday close $21.13

Encana Corp, Canada’s largest natural gas producer, said it would buy Athlon Energy for $5.93 billion in cash, excluding debt, as it accelerates its plan to focus on more-lucrative oil and natural-gas liquids (NGLs).

** TONIX PHARMACEUTICALS HOLDING CORP, Friday close $13.96, -47.28 pct premarket

The company said its lead pain drug had failed the main goal of a mid-stage study testing if it reduced pain experienced by patients by the 12th week of the trial.

** DREAMWORKS ANIMATION SKG INC, Friday close $22.36, +20.75 pct premarket

Japan’s SoftBank Corp is in talks to acquire DreamWorks, the Hollywood studio behind the “Shrek” and “Madagascar” movie hits, a person with knowledge of the situation said.

** ALIMERA SCIENCES INC, Friday close $4.925, +21.62 pct premarket

** PSIVIDA CORP, Friday close $4.29, +13.75 pct premarket

U.S. Food and Drug Administration approves the companies’ vision-loss treatment Iluvien after three rejections. PSivida said the approval entitles it to get milestone payment of $25 million.

** MERCK & CO, Friday close $59.39

The company’s new immune system drug, Keytruda, has produced encouraging results in early tests against bladder cancer, according to a company-sponsored study, prompting the firm to prepare a clinical trial later this year.

** DIGITAL ALLY INC, Friday close $17.63, +2.10 pct premarket

The wearable camera maker received order from U.S. military for complete video evidence gathering system. The company said the initial order is valued at $200,000.

** CROSS COUNTRY HEALTHCARE INC, Friday close $9.02,

UBS raised its rating on the provider of healthcare recruiting and staffing services to “buy” from “neutral”, according to

** PIONEER NATURAL RESOURCES CO, Friday close $196.6

The U.S. shale resources producer plans to double its U.S. exports of condensate, an ultra-light oil, to 50,000 barrels per day (bpd) next year, its chief executive said on Monday.

** LOCKHEED MARTIN CORP, Friday close $181.58

The defense supplier said it will buy a European-built military communications satellite for South Korea as part of a $7 billion deal to supply Seoul with 40 F-35 fighter jets, in what industry observers call among the most unusual “offset” agreements ever to accompany a major arms sale.

** CYTRX CORP, Friday close $2.78, +6.47 pct premarket

The drug developer said the U.S. Food and Drug Administration granted orphan drug status to its lead experimental drug to treat small cell lung cancer, ovarian cancer and brain cancer. The drug, Aldoxorubicin, is currently in late-stage trials under a Special Protocol Assessment with the FDA as a second-line treatment to evaluate safety and effectiveness in patients with cancerous tumors.

** PUMA BIOTECHNOLOGY INC, Friday close $246.07, +0.58 pct premarket

The biopharmaceutical company said its experimental lung cancer drug was safe to be administered with an already approved treatment for the disease in a mid-stage study. (Compiled by Anannya Pramanick; Edited by Maju Samuel)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below